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Introduction: Alkaptonuria is an iconic disease, dating back to the Egyptians and has continued to 
prove a valuable teaching tool to many medics as an example of an inborn error of metabolism. In 
recent years, much progress has been made on understanding the condition and its symptoms; the 
single defective gene has been identified and cloned. In humans novel phenotypic presentations of 
the condition have been documented, and in vitro models developed to understand the disease. 
Furthermore, a mouse model has studied and most recently clinical trials into the effectiveness of 
nitisinone have been undertaken. Nitisinone has been on a miraculous journey from its discovery as a 
weed killer to its effective treatment in hereditary tyrosinaemia type – 1.  
Areas covered: The authors describe research into nitisinone and its application in model and human 
systems in both hereditary tyrosinaemia type 1 (HTT-1) and Alkaptonuria. The published literature was 
searched for outputs relating to “Alkaptonuria”, “ochronosis”, “nitisinone”, “hereditary tyrosinaemia 
type 1”. Any paper not in English or had no translation were excluded.  
Expert opinion: Now nitisinone is being studied for use in Alkaptonuria and this paper documents the 
journey of AKU and the promising potential of nitisinone in the treatment of Alkaptonuria.  
1 Introduction 
Alkaptonuria (AKU) (OMIM: 203500) is a rare disease that currently has no approved therapy. 
The condition does not lead to a shortened life, but it has a significant effect on quality of life 
of those with the disease [1]. Over 100 years ago, Sir Archibald Garrod used AKU to illustrate 
the concept of Mendelian inheritance, owing to the autosomal recessive nature of AKU [2], it 
became a disease of both historic and medical interest. The condition is classified as rare or 
ultra-rare; its prevalence is documented at approximately 1:100,000-1:250,000, with 
hotspots reported in the Dominican Republic and Slovakia where its prevalence increases to 
approximate 1:19,000 [1]. AKU is a metabolic disease of tyrosine catabolism, caused by a 
deficiency or a defect of the enzyme homogentisate 1,2-dioxygenase (HGD) (EC number: 
1.13.11.5) that catabolises homogentisic acid (HGA) [3]. This catabolism opens the benzene 
ring of the HGA molecule to the linear maleylacetoacetic acid. The HGD enzyme is believed to 
be highly specific in its action and is produced mainly by hepatocytes in the liver and is present 
in the kidneys [1, 4]. In the absence or defect of the HGD enzyme, HGA accumulates 
systemically; in the cells and tissues it polymerises to benzoquinone acetic acid which 
pigments and turns black, a process known as ochronosis [5-7]. This process has some 
similarities to the conversation of tyrosine to melanin. Ochronosis is one of the features of 
 
 
the clinical triad of AKU and leads to systemic ochronosis, over time, of multiple collagenous 
tissues leading sufferers to progress to having ochronotic osteoarthropathy [8]. The signs and 
symptoms of this clinical triad associated with AKU occur sequentially. The first detectable 
sign of AKU, and the only symptom present in the paediatric population, is black or dark urine. 
This symptom is clearly seen in the paediatric population as it is visible in the nappy, but can 
often be mis-diagnosed due to the rarity of the condition and the lack of familiarity with it 
and its symptoms by healthcare practitioners. This darkening is the result of the oxidation of 
excess HGA that has been excreted via the renal system [9]. Ochronosis appears to occur as 
the renal system struggles to clear the HGA and so the excess HGA remaining in the body 
appears to accumulate in the connective tissues of the body where it undergoes 
polymerisation [1]. As well as in connective tissues of the musculoskeletal system, ochronosis 
can also occur in the eyes, ears, renal system, skin and cardiovascular system [4, 8, 10]. 
Ochronotic osteoarthropathy, the final feature of the triad, occurs due to the cumulative 
effect of the HGA polymer deposition in the collagenous connective tissues, specifically the 
hyaline cartilages of weight bearing joints [1]. The pigmentation commences deep in the 
cartilage associated with individual chondrocytes and will spread out to the cartilage matrix 
[11]. The significant anatomical changes in the joint are the result of the loss of subchondral 
bone due to aggressive bone resorption as a result of the stiff ochronotic cartilage preventing 
load being applied to the subchondral bone. This is further compounded by low bone turnover 
due to the presence of ochronotic pigment in tissues preventing resorption. The hyaline 
articular cartilage also undergoes significant change, it changes mechanically due to the stiff 
ochronotic pigment, as well as the presence of ochronotic pigment changing its biochemical 
properties. All of these factors contribute to the destruction of the joint and increase the 
susceptibility to injury and damage as the mechanical properties of the joint are altered [12]. 
The most common treatment for this arthropathy will result in the patient requiring a joint 
replacement, particularly of the weight bearing joints (hip, knee and shoulder) [5].  
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Our manuscript includes research outputs that were generated from searching online 
literature databases PubMed and Google Scholar using the search terms “Alkaptonuria”, 
“ochronosis”, “nitisinone”, “hereditary tyrosinaemia type 1”. There were no limitations on 
the dates used to exclude papers. The authors only read papers that were published in English 
or had a freely available translation from their native language.  
The authors describe in vitro and in vivo  research into nitisinone and its application in model 
and human systems in both hereditary tyrosinaemia type 1 (HTT-1) and alkaptonuria.  
 
3 Potential therapies 
At present, there is no cure for AKU and the associated ochronotic osteoarthropathy, 
treatment/management options are limited and often palliative with a lack of curative or 
preventative options [1]. Physiotherapy, which is aimed at maintaining mobility and reducing 
the rate of musculoskeletal decline has been utilised [13]. Pain management is frequently 
administered, although the delivery of any analgesia can be impacted due to the ochronosis 
of tissues, particularly when considering the spine and shoulders [14-18].  Due to the lack of 
a disease modifying therapy, ultimately, multiple joint replacements are needed [19-21]. All 
of these only treat the symptoms, they do not deal with altering, removing or reducing the 
causative molecule, HGA, from the body.  
A low protein diet, to limit the intake of the preceding amino acids that are broken down to 
HGA; tyrosine and phenylalanine has been suggested as a potential therapy for AKU patients, 
it is incredibly difficult to maintain and is thought to be ineffective due to this reason and the 
fact that less than 10% of dietary protein is broken down via the HGA pathway. It is difficult 
to sustain this in the long term and can be problematic during childhood as limiting intake of 
protein can have an effect on development but compliance may also be problematic [22, 23].  
It is also clear that not all tyrosine and phenylalanine comes from dietary intake, some is 
generated through tissue catabolism[22].  
Anti-oxidant therapies, such as ascorbic acid (ASC) more commonly known as Vitamin-C, have 
been suggested as potentially inhibitors of the polyermisation of HGA, showing effectiveness 
in reducing the conversation of HGA to its quinone intermediate on the way to ochronotic 
pigment, it did not reduce the amount of HGA excreted in the urine [24]. A greater 
understanding of the tyrosine degradation pathway also highlights that ASC is a co-factor for 
4-hydroxyphenylpyruvate dioxygenase, which causes increased HGA production by ensuring 
 
 
the conversion of 4-hydroxyphenylpyruvic acid to HGA, this may actually increase the amount 
of HGA formed and therefore the amount of HGA available to undergo the polymerisation 
process to pigmentation. Evidence of the use of ascorbic acid in the paediatric population 
demonstrated a concerning increase in the urinary concentration(s) of HGA which may 
facilitate pigmentation in earlier age groups [25]. This increase in HGA levels may also 
contribute to the formation of renal oxalate stones. This is concerning, as AKU patients are 
already at high risk for developing renal calculi and prostatic calculi in males [26-28]. The 
mechanism of calculi formation in AKU patients is unclear, it is documented that the 
development of calculi forms in a similar manner to that in the general population. However, 
the literature reports that there is an increase in the prevalence of any type of stones; renal, 
prostatic or even submandibular in the AKU population [29, 30]. Formation of oxalate stones, 
requires an interaction between the renal system epithelia and the crystal. Usually the 
crystals formed within the system are discharged in the urine, small crystals that become 
attached to the epithelial lining are thought to be digested by macrophages or lysosomes. 
Factors that initiate the formation of stones include reduced urinary volume or alterations in 
urinary pH or a combination of these factors [31]. Given that AKU patients are excreting gram 
quantities of HGA daily in their urine [32], this will cause perturbations in their urinary pH and 
may be a factor in the increased formations of stones in renal, or any other excretory, or 
secretory system in these patients. The association of ochronotic pigment and calcium 
crystals has previously been documented both in calculi, but also in other calcified 
pathological areas of the body suggesting an overlap in the process [33]. it is not ultimately 
clear exactly how HGA or calculi interact and further work is needed in this area to decrease 
the disease burden in AKU patients [34]. It has been shown that liver transplantation is a 
successful means to eradicate HGA from the body, due to the presence of the HGD enzyme 
in the donor liver hepatocytes [35]. This halted the progression of the disease, but is unlikely 
to have reversed the presence of any ochronosis that already existed in the tissues.   
 
A drug under current investigation for use in AKU is nitisinone [1], an inhibitor of 4-
hydroxyphenlypyruavte dioxygenase, which is also present in the tyrosine degradation 
pathway [36]. Although nitisinone is not routinely prescribed for AKU, it is administered to 
patients who are being treated at the National AKU centre based in Liverpool [37]. This drug 
 
 
is licensed for treatment of hereditary tyrosinaemia type 1, another, more severe disorder of 
tyrosine metabolism [38].  
 
4 Discovery of Nitisinone 
Nitisinone is a naturally occurring herbicide discovered when observations were made of the 
reduction in the number of other plants growing in close proximity to the bottlebrush plant 
(Callistemon) [39]. The absence of other species from around the bottlebrush suggested an 
effect from inhibition of pathway(s) affiliated with growth. It was discovered that the chemical 
known as Leptospermone, which is present in the soil around the plants had a bleaching 
effect, amongst others, on neighbouring plants. Leptospermone belongs to the triketone 
family and impedes chloroplast development by 4-hydroxyphenylpyruvate dioxygenase 
(HPPD) inhibition; HPPD is an enzyme involved in the catabolism of tyrosine and is integral to 
the production of a number of natural plant products [40, 41]. The discovery of the triketone 
family, of which Leptospermone was an early finding, led to the discovery and development 
of nitisinone. The initial work in understanding how nitisinone worked was undertaken by 
Zeneca Agrochemicals following indications that it inhibited the actions of another enzyme 
which uses tyrosine as a substrate; tyrosine hydroxylase. Further work on nitisinone by 
Zeneca Central Toxicology Laboratories clarified that Nitisinone did not inhibit tyrosine 
hydroxylase or tyrosine aminotransferase, but in fact was a potent inhibitor of HPPD [38].  
 
Whilst this paper is interested in the potential of nitisinone in AKU, it is another disorder of 
tyrosine metabolism where nitisinone would initially prove its value as a therapy. AKU is not 
shown to reduce longevity, however hereditary tyrosinaemia type 1 (HT-1)(OMIM #276700) 
is a much more life limiting disorder which if left untreated can result in hepatocellular 
carcinoma and other severe complications leading to death at a young age [42]. Prior to the 
discovery and availability of nitisinone, it was liver transplantation that was the go to therapy 
for HT-1. In the HT-1 paediatric population(s), the administration of nitisinone in combination 
with a protein restricted diet, to individuals under 2 months of age sees the 4 year survival 
rate increase to 94%, compared to protein controlled diet alone at 29% [43].  
 
The ongoing work to understand the mechanism of action of nitisinone would see it 
administered to multiple animals in order to test its efficacy and toxicity. Administration to 
 
 
rats produced a marked increase in the presence of tyrosinaemia in plasma and the aqueous 
humour of the eye; 2500nmol/L and 3500-4000nmol/L respectively [44]. These tyrosinaemias 
were produced by the administration of 0.3 μmol/kg/day and 30 μmol/kg/day nitisinone, 
which resulted in tyrosinaemia occurrence in 38% and 75% of subjects. Whilst an increase in 
presence of corneal opacities as a result of tyrosinaemia was noted, the question raised is one 
of what systemic factors within individual subjects may contribute, or protect against this 
symptom? Variation in plasma concentrations of tyrosine, or abundance of enzyme(s) or their 
level of activity in the tyrosine metabolic pathways may act as rate limiting, and therefore, 
symptom limiting factors. 
 
5. Why is it needed in AKU? 
AKU has encountered a vast number or potential therapies, many of which have had varied 
success, but the bottom line has always been that there is no effective therapy, only 
management by palliative care such as physiotherapy or pain relief and then surgical 
replacement of the affected joint.  
 
Research on HT-1 has again given hope to patients with the condition, and the hope is that it 
may stand to benefit patients with AKU, similar to that seen in the discovery, development 
and use of nitisinone. Gene-editing therapies such as those utilising the CRISPR–Cas9 have 
been utilised in vivo to show that this technology can rescue diseased phenotypes, such as 
HT-1 in adult mice [45], or convert them to a more benign phenotype [46]. Most recently this 
technology has shown that it can produce phenotypic rescue by utilisation in utero, again 
correcting the potentially lethal HT-1 phenotype [47]. The ability to edit the genetic make-up 
of hepatocytes in this way holds promise for other diseases of the tyrosine metabolic 
pathway, including diseases such as AKU. In AKU, it is known that only the HGD enzyme is 
missing and thus a single defect correction would be sufficient to ensure correction of disease 
[48, 49]. Delivery of the functional HGD code to hepatocytes is significant here, to ensure that 
subsequent tyrosinaemias in the pathway are not induced based on the locality of the 
cytosolic production of tyrosine metabolic enzymes in the hepatocytes of the liver.  
 
6. Effectiveness of Nitisinone in AKU 
 
 
A positive reduction in HGA levels has been seen in associated with the use of this drug [50, 
51]. However, there have been undesirable side effects including corneal opacities and 
limited evidence have restricted universal use to date [52]. These corneal side effects are 
most commonly described in HTT-1 patients at a prevalence of 7.4-8.7% based on the studies 
undertaken [53, 54]. The doses of Nitisinone used in HTT-1 treatment is approximately 20 fold 
higher than that used in AKU and therefore the reported complications of corneal opacities 
in the AKU literature is much rarer [55].   Previous studies have utilised endpoints in relation 
to the musculoskeletal system, with hip range of motion as a primary outcome and other 
musculoskeletal actions as secondary measures. These parameters did not show significant 
enough improvement to validate the use of nitisinone for AKU [51]. The interesting data in 
the study demonstrated that the urinary and plasma HGA levels were reduced by at least 95% 
in both cases, in some instances to undetectable levels, replicating non-AKU levels [51]. The 
HGA lowering efficiency shown in this trail replicated the effect seen in the preliminary study 
demonstrating the positive effect of low dose of nitisinone on the presence of HGA in urine 
of a small cohort of AKU patients [56]. Most recently, a specialist NHS commissioned service 
gave 2mg of nitisinone every other day for 3 months and daily thereafter to a group of 58 
patients, with 28 of these having 2 years’ worth of nitisinone treatment in Liverpool, has again 
shown the significant effect of nitisinone on the reduction of HGA in urine and serum, with 
reductions approaching 95% and over 80% respectively [37]. Similar extremely positive 
outcomes in the SONIA-1 (Suitability of Nitisinone in Alkaptonuria) study with promising 
clinical results in demonstrating a 98.8% reduction in urinary excretion of HGA over 24 hours, 
when patients are administered 8mg/day [57]. In other work, low doses of nitisinone have 
also demonstrated efficacy in patients in the paediatric age group[57, 58].  
 
The effect of nitisinone on HGA levels is clearly positive in terms of potential benefit to 
patients. It has the ability to reduce ochronosis by removing or reducing the causative 
molecule HGA from the body. Over time the polymerisation of HGA has many known and 
potentially unknown effects – the removal of the HGA molecule altogether ameliorates any 
issues that may arise due to its presence. This is ideal in terms of reducing disease burden for 
the patient and returning to a normal quality of life across the lifespan [59]. The discovery of 
a murine model which presents with the AKU genotype and phenotypic symptoms similar to 
the human has aided in the understanding of the disease process and the effectiveness of 
 
 
nitisinone [60]. Whilst the only symptom of AKU visible in the paediatric age group is the 
homogentisic aciduria, the timing of manifestation of ochronosis in tissues is still unclear, but 
appears to be around the 3rd or 4th decade. The mouse has proved useful in demonstrating 
that the pigmentation process commences around week 15 of life and that nitisinone arrests, 
but does not reverse ochronosis  [50, 61].  
Little is known about the systemic effects of nitisinone in humans, however, it has been shown 
to have no adverse effects on osteoarticular cells, which without the presence of nitisinone 
in AKU are subject to intra and extracellular ochronosis [62, 63]. This all provides promising 
evidence for the use of nitisinone and the reduction of HGA, limiting the ochronosis of tissues.  
 
The main side-effect of administration of nitisinone is the accompanying tyrosinaemia that 
develops in some of the patients due to the increase in the presence of plasma tyrosine levels. 
The most concerning side effect that has been seen in individuals with tyrosinaemia is the 
potential for cognitive impairment in terms of development and beyond. In the early studies 
that examined this in HTT-1 patients, there were suggestions that approximately 35% of 
school age children had some form of difficulties [54]. However, this study lacked what are 
now considered routine psychometric tests. Further studies have identified variation in the 
HTT-1 population in terms of their cognitive function with one of the limiting factors being 
the small number of patients that were present in each of the studies [64]. The withdrawal of 
nitisinone or non-compliance has other complications such as neurological crises [42, 65]. 
There are several proposed mechanisms for the potential neurological developmental delay 
that is seen in HTT-1, they all relate to movement of monoamine molecules such as tyrosine 
and tryptophan into the brain, as well as other more peripheral or central nervous system 
effects [66-68]. It is important in the study of AKU in particular to understand when the most 
optimal treatment time for commencing nitisinone is. Whilst the information of the effect of 
HGA on the body in the paediatric age group is limited, it does not appear to have the 
detrimental effects that it, or the subsequent polymer has in the adult population. Similarly, 
if tyrosinaemias associated with the administration of nitisinone in the paediatric population 
of HTT-1 patients produce cognitive issues in development a decision has to be made as to 
when would be appropriate to commence nitisinone therapy in AKU. Further work and 
understanding in this area is needed, but data from the AKU mouse suggests that monoamine 
neurotransmitters in the brain tissues of AKU mice did not change following the 
 
 
administration of nitisinone [68]. The increased plasma tyrosine causes retinal keratopathy 
and/or corneal opacities in the eyes of AKU patients caused by the deposition of tyrosine 
crystals [55, 69, 70]. The presence of tyrosine crystal deposits in the ocular tissues is not fully 
understood, however cessation of nitisinone results in disappearance of crystals and 
symptoms as soon as 2 weeks after halting therapy, although deposition may still occur even 
in the absence of symptoms and this should be monitored closely. The monitoring of the 
levels of tyrosine and HGA are key indicators to assess efficacy of nitisinone therapy in 
patients administered nitisinone in pre– and post-administration and to ensure that patient 
safety is maintained, this has been benefitted by the development of techniques to assess 
both HGA and tyrosine simultaneously in urine samples [71]. This technique has been further 
enhanced to measure nitisinone levels in combination with HGA and tyrosine within serum 
samples [30]. 
The most recent clinical trial examining the effect of nitisinone in AKU patients: Suitability of 
Nitisinone in Alkaptonuria 2 (SONIA 2) has shown that patients treated for 3-12 months had 
a 99.5% reduction in the HGA they excreted in their urine and a 97.5% reduction in the HGA 
detectable in their blood after one year. The patients in this study tolerated nitisinone 
remarkably well with only 5 patients showing ocular problems and being switched to a lower 
dose of nitisinone. The investigators conclude that the “SONIA 2 one year study data shows 
that nitisinone treatment of AKU patients results in a significant reduction of HGA in the urine 
and blood with no safety concerns.” The strength and success of these results has led Swedish 
Orphan Biovitrium to seek market authorisation from the European Medicines Agency for the 
drug to be used in treating AKU [72].  
Recently it has been shown that Raman spectroscopy may be a useful tool for monitoring 
ochronosis in vivo. The ex vivo analysis of cartilage samples from the hips and ears of 
individuals with AKU have shown unique cartilage spectra from those with the presence of 
ochronotic pigment, whilst cartilages without ochronosis demonstrated a spectra that was 
consistent with normal cartilages [73]. Raman has the potential to be used in vivo via 
transdermal analysis of cartilage, it has been used on analysing cartilage and bone samples 
from patients with Osetogenesis Imperfecta (OI). The technique of Raman spectroscopy has 
already provided useful information in a clinical setting on the composition of bone matrix via 
transcutaneous acquisition of osteoporosis and osteogenesis imperfecta [74, 75]. In AKU, one 
of the early observable tissues that undergoes ochronosis is the ears, Raman has the potential 
 
 
to be used for real-time analysis of this tissue, as well as the longitudinal monitoring of 
patients who may at some point need nitisinone administration. If spectral analysis of tissues 
demonstrated the presence of ochronotic pigment the affected individual could be placed 
onto nitisinone to halt progression of the condition. Similarly, the use of Raman to monitor 
osteoarticular tissues, has been shown and this could also be applied to these tissues in AKU 
patients. Prior to the use of Raman spectroscopy clinicians and researchers utilised a robust 
and validated scoring index the AKU severity score index (AKUSSI) which characterised a pre-
ochronotic and then a much more rapidly progressing ochronotic state of the disease, which 
was known by clinicians and researchers but up until this point had been difficult to quantify 
and demonstrate. This tool also demonstrates the burden of the disease [76]. As AKU research 
has gathered traction and more patients have become involved in research, the AKUSSI has 
clearly demonstrated the effect of nitisinone on the various parameters of the index. It shows 
how effective the therapy is, adding further validation to its use in AKU, it reduces HGA but 
also demonstrates numerous secondary important features of monitoring patients and their 
tissues which become symptomatic during the course of the disease [77, 78]. The efficacy of 
nitisinone is clearer seen in longitudinal studies spanning 3 years examining multiple patients 
with AKU, not only reducing HGA, but also arresting ocular and auricular ochronosis[59].  
 
7. Expert Opinion 
Nitisinone has gone a significant journey since its discovery as a weedkiller to becoming a 
wonder drug for treating potential fatal conditions. The early trial of the therapy in AKU was 
disappointing, but subsequent in vitro, animal and now clinical trial data suggest that a 
primary outcome measure as the reduction of HGA in plasma and urine as an end point have 
renewed hope for AKU patients around the world. The absence of ochronosis in mice 
administered nitisinone through drinking water shows a clear efficacy for the drug and 
correlation with the reduction of HGA resulting in the absence of pigmentation suggests that 
in model systems that this should be replicated in humans.  
There are still challenges and research to be done to understand the variability in presentation 
of tyrosinaemia and ocular pathologies associated with nitisinone administration in AKU 
patients, it is likely there are other variable factors within individuals that are responsible for 
these variations given that the dose of nitisinone administered in trials affects some but not 
others. The validation of Raman spectroscopy as a technique that has the ability to identify 
 
 
differing spectra of tissues with and without ochronosis is an exciting proposition particularly 
as it has already been validated as being able to detect pathological matrix in other 
osteoarticular tissues. This may prove useful for monitoring the absence/presence of 
ochronosis and enable the therapy to be targeted to an individuals presentation of ochronosis 
in tissues, given there is variability within an individual’s connective tissues (different tissues 
pigment at different rates) and across affected individuals. This may also mean that there is a 
reduced requirement for younger populations needing the administration of nitisinone, 
which still requires further research in AKU populations. AKU may also benefit from future 
advances in gene replacement or enzyme replacement therapies, only time will tell. The fact 
that this disease is the result of a single enzyme defect that causes elevation in a single 
tyrosine metabolite suggests that it may be a useful model to look at gene therapies for more 
complex conditions where some of this information is yet to be clarified.  
AKU is an iconic disease due to Garrod’s work and demonstrating that the disease results from 
inheritance. Since then the defective enzyme and gene have been identified, the causative 
molecule elucidated and studied and potential therapies have come and gone. 
There is still work for researchers to do in trying to understand the biochemical changes that 
occur to HGA in the polymerisation process and how this promotes binding to extracellular 
matrices. These questions will need to be answered to look at removing established 
ochronosis from patient tissues. The current landscape suggests that any therapy that inhibits 
the presence of ochronosis, by removing the presence of HGA altogether, is the most efficient  
and sensible way forward.  
At the moment the effectiveness of nitisinone looks to be a very positive therapy for an iconic 
condition that has benefitted from dedicated patients, advocates and researchers in recent 
years to make ground-breaking discoveries about the condition. The recent release of the 
SONIA 2 results and the move by Swedish Orphan Biovitrium to seek market authorisation 
from the European Medicines Agency for the use of nitisinone to treat AKU suggests that this 
“weedkiller to wonder drug” story may have another chapter to be written. This will see 
patients diagnosed with an iconic medical condition be able to receive treatment and the 
prospect of ochronosis affecting them disappears.  
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